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Of all special fields in medicine, 
internal medicine and psychiatry 
probably play the most important 
roles in general medical practice. 
This has always been so, but there 
has also always been a gap be-
tween the clinical approach to the 
medical aspects of the total treat-
ment of a person, and to the psy-
chiatric aspects. This gap, which 
for many years has alienated psy-
chiatry from the other parts of 
medicine, has only been bridged in 
the last two decades. Since the 
early 1950's psychiatric thinking 
and practice has moved much closer 
to general medical procedures, so 
that treatment of many psychiatric 
patients has become more rational, 
more understandable and more 
practical for the non-specialist. 
If psychiatric treatment today is 
a major concern of general medical 
practice, psychopharmacology has 
been one of the most important fac-
tors in this development. New 
and effective pharmacological treat-
ments of various psychiatric dis-
orders have made it possible for 
any physician to treat patients who 
previously had to be hospitalized 
and could be treated only by psy-
chiatrists. In making this claim for 
the pharmacotherapy of psychiat-
ric disorders, I do not wish to im-
ply that the fine arts of interview-
ing, listening and psychological 
understanding are no longer needed 
by the doctor; they still are and 
probably always will be among the 
most important skills of any good 
physician. I simply want to make 
the point that psychopharmacology 
today has grown into a system of 
empirical and rational procedures 
which can be studied and acquired 
by anyone who is motivated to do 
so. To acquire knowledge and skill 
of psychopharmacological proce-
dures neither calls for particular 
assets of temperament or personal-
ity nor dedicated immersion into 
esoteric speculations and polysyl-
labic terminology. 
What is Psychopharmacology? 
Psychopharmacology is a new 
scientific discipline which was born 
in the first few years of the second 
half of our century. It is a discipline 
which deals with psychotropic or 
psychoactive drugs, i.e., drugs 
which influence consciousness, 
mood and behavior. Psychopharma-
cology, which has played such an 
important role in bringing psychia-
try back into the fold of general 
medicine, is concerned with four 
principal aspects of psychotropic 
drugs: 1) indications for, and dos-
age of, psychotropic drugs; 2) side 
effects and complications of these 
drugs and their management; 3) 
understanding of the mechanisms of 
action of psychotropic drugs 
through the development of opera-
tionally defined and measurable re-
search procedures; 4) development 
and screening of new substances in 
this field. The first two of these as-
pects primarily concern the clini-
cian; the latter two lie more within 
the field of the researcher. 
Following the discovery of chlor-
promazine, the first of a group of 
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entirely new drugs for the treat-
ment of mental disorders, it became 
clear within a few years that the 
new psychotropic drugs had made 
a tremendous impact on three 
areas: 1 ) the public, for whom-
virtually overnight-tranquilizers 
became a household word and a 
multimillion-dollar business; 2) re-
search, where the new discipline 
of psychopharmacology was estab-
lished in the wake of these discov-
eries; 3) treatment, where the new 
drugs made possible an almost rev-
olutionary new approach to the 
therapy for many psychiatric dis-
orders. 
A number of psychotropic drugs 
have, of course, been known and 
used by man for a long time. Al-
cohol, caffeine and certain narcot-
ics are the oldest psychotropic 
agents known. The discovery of 
their properties has been lost in 
the dawn of recorded history. But 
with the advent of scientific medi-
cine, systematic research during the 
past century led to the develop-
ment of anaesthetic drugs and, 
later, to the introduction of a va-
riety of hypnotic and sedative 
agents. Thus, after the empirical 
discovery of intoxicants and stim-
ulants, medical research discovered 
remedies for some of the universal 
ills of mankind, i.e., pain, insomnia 
and anxiety. Effective drugs for 
more specific uses in the treatment 
of mental and emotional disorders 
have been systematically developed 
since two French psychiatrists, De-
lay and Deniker (1952), adminis-
tered chlorpromazine (Thorazine) 
for the first time to agitated psy-
chotic patients and noted the 
extraordinary tranquilizing effect of 
this drug. 
Pharmacotherapy in Psychiatric 
Disorders 
Although the title of my paper 
is "Psychopharmacological Proce-
dures," what I really intend to talk 
about is pharmacotherapeutics with 
psychiatric patients. At this point, 
I would like to remind you that 
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psychiatry is less fortunate than 
other branches of medicine, be-
cause (with very few exceptions) 
it lacks objective criteria for diag-
nosis as well as knowledge about 
the etiology of most of the condi-
tions for which a psychiatrist has 
to treat his patients. This does not 
mean that psychiatric diagnosis is 
entirely subjective, but it does mean 
that practically all psychiatric diag-
nosis is based primarily on the ob-
servation of behavioral deviations. 
The causes of the major psychoses 
are still unknown, although a great 
deal of promising research is going 
on in this area. The origin of 
neurotic disturbances is better un-
derstood but is also still subject to 
controversy between proponents of 
psychoanalysis, learning theory and 
genetic or other somatic factors. In 
spite of all these theoretical un-
certainties, we now have a variety 
of effective pharmacological treat-
ments in psychiatry, and even if 
their mechanisms of action are not 
always clearly understood, many of 
these treatments have empirically 
proven their worth. 
Rather than involve you in the 
problems of psychiatric diagnosis 
and classification, I should like to 
discuss the four major symptomatic 
conditions which can be effectively 
treated with psychotropic drugs. 
These four conditions are: 1 ) psy-
chomotor excitement; 2) tension 
and anxiety; 3) depression; 4) per-
ceptual and cognitive disorders 
(e.g., hallucinations and delusions). 
Let me briefly define these well-
known behavioral deviations or 
mental symptoms. 
Psychomotor excitement is char-
acterized by restless, overactive, 
agitated, noisy, boisterous and dis-
inhibited behavior; a feeling of be-
ing driven-being under pressure 
-with the mood being either one 
of aggressive anger or excessive 
elation. Usually, pronounced psy-
chomotor excitement is associated 
with insomnia and sometimes with 
clouded consciousness, i.e., confu-
sion and delirium. 
Tension and anxiety are char-
acterized by aimless restlessness and 
autonomic signs of sympathomi-
metic (adrenergic) arousal, e.g., 
tachycardia, sweating, increased 
blood pressure, mydriasis. At the 
same time the patient feels uncom-
fortable, unable to relax and-
when not only tension but also 
anxiety is present-apprehensive 
and threatened in some undefinable 
manner. Tense and anxious pa-
tients, as a rule, also suffer from 
insomnia. 
Perceptual and cognitive disor-
ders occur mostly in psychotic con-
ditions and indicate impaired con-
tact with reality. Examples of 
symptoms occurring in this cate-
gory are: hallucinatory perceptions, 
in one or several sense modalities, 
without any corresponding objec-
tive stimulation; delusional ideas, 
i.e., false and persistent beliefs 
which cannot be corrected by ra-
tional proof that they are un-
founded; a generalized thinking 
disorder leading to irrational and 
bizarre forms of reasoning. 
Depression is behaviorally char-
acterized either by agitation or, 
more typically, by psychomotor re-
tardation, i.e., a general slowing 
down of all spontaneous and re-
sponsive activity, an overall in-
crease of inhibition and reduction 
of energy output. Most important 
is the core symptom, a subjective 
background of an all pervasive 
feeling of dejection, pessimism and 
hopelessness which not infrequently 
leads to attempted or completed 
suicide. 
Classification of Psychotropic 
Drugs 
Having thus classified-though 
somewhat roughly-the four prin-
cipal psychiatric conditions which 
can be effectively treated with psy-
chotropic drugs, let me now give 
you the brief and simple classifica-
tion of psychotropic drugs which 
has been proposed in the report, 
"Research in Psychopharmacol-
ogy," published by a World Health 
Organization scientific group 
( 1967) . The report distinguishes 
five categories of drugs. The first 
category is Neuroleptics-often re-
ferred to as major tranquilizers or 
antipsychotics-which are repre-
sented by the phenothiazines, the 
butyrophenones and the thioxan-
thenes, as well as by the reser-
pine derivatives. The second cat-
egory is Anxiolytic Sedatives-
often referred to as minor tran-
quilizers-which are represented 
by meprobamate and its derivatives, 
chlordiazepoxide (Librium) and its 
derivatives, and barbiturates. The 
third category is Antidepressants, 
represented by monoamine oxidase 
(MAO) inhibitors or imipramine 
and other tricyclic compounds. The 
fourth category is Psychostimu-
lants, represented by the ampheta-
mines, methylphenidate (Ritalin) 
and pipradrol (Meratran) and by 
caffeine. The fifth category is Psy-
chodysle pt ic s (hallucinogens), 
which are mainly represented by 
lysergic acid diethylamide (LSD), 
mescaline, psilocybin, dimethyltryp-
tamine (DMT) and cannabis (mar-
ijuana, hashish .or bhang). 
Clinical Applications 
Psychostimulants and 
Psychodysleptics 
Let us first look at the last two 
categories of psychostimulants and 
psychodysleptics, because they have 
few clinical applications and we 
can rapidly dispose of them. Psy-
chostimulants are specifically indi-
cated for the treatment of narco-
lepsy. Sometimes they are useful 
in states of chronic lassitude, such 
as may be seen following a pro-
tracted disease, e.g., a virus infec-
tion. The amphetamines may also 
be helpful in programs of weight 
reduction because of their anorexo-
genic effect. In the treatment of 
depressive conditions, psychostim-
ulants play a very minor role, be-
cause a severely depressed patient 
requires more than a "lift" or 
"boost." If a depressed patient's 
state of arousal is increased by a 
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psychostimulant, he is often ren-
dered more tense and sleepless and 
may well become more depressed. 
Sometimes, but rarely, an ampheta-
mine or Ritalin may be helpful in 
the treatment of certain depressive 
states, but only when the depres-
sion is in its very beginning or 
already fading out. During a full-
blown depression, psychostimulants 
are contraindicated. Because physi-
cal tolerance of and psychological 
dependence on the amphetamine-
like psychostimulants develop rap-
idly, these drugs should only rarely 
be prescribed. This is the conclu-
sion reached in the report entitled 
"Control of Amphetamine Prepara-
tions" prepared by a special com-
mittee* which had been appointed 
in Britain to study the place of 
the amphetamines in clinical 
medicine. 
The psychodysleptics, i.e., LSD 
and similar drugs which produce 
strange alterations of consciousness 
-their current popularity notwith-
standing-have no clearly estab-
lished therapeutic indications. Their 
use is mainly experimental, al-
though considerable literature exists 
on the use of LSD in neurotic con-
ditions, behavior disorders and al-
coholism. Whether or not these 
drugs are really effective in these 
disorders and, if so, in what dosage 
and under which conditions, will 
be shown by the outcome of a 
number of controlled studies, the 
results of which will not be avail-
able for another three to five years. 
There is also the possibility that 
the recently isolated active princi-
ple of marijuana-tetrahydrocan-
nabinol (THC)-might find some 
clinical applications, perhaps in the 
treatment of depressions. At the 
present time, however, the applica-
tion of the entire category of psy-
chodysleptic drugs, which manifest 
their action mainly through disor-
ganization of perceptual, cognitive 
* J. Chappell, W. W. Fulton, M. M. 
Glatt, W. L. Rees and C. W. M. 
Wilson. 
and affective processes, is still in 
the experimental stage. 
Therapeutic Applications of 
Neuroleptics and Anxiolytic 
Sedatives (Tranquilizers) 
States of Excitement 
Effective agents in the treatment 
of acute excitement and acute or 
chronic states of tension and anxi-
ety are the neuroleptics and the 
anxiolytic sedatives. Both types of 
drugs are often referred to as tran-
quilizers. However, if one chooses 
to do so, he should make a clear 
distinction between the major tran-
quilizers (neuroleptics) and the 
minor tranquilizers ( anxiolytic sed-
atives). There are distinct clinical 
and pharmacological differences be-
tween the two types of tranquiliz-
ers. The only drugs which can ef-
fectively reduce specific psyci;otic 
symptoms-hallucinations, delu-
sions and psychotic thought disor-
der-are the major tranquilizers. 
But both the major and the minor 
tranquilizers will reduce psychomo-
tor excitement, tension and anxiety, 
although the minor tranquilizers 
will do it more effectively. 
Many of the anxiolytic sedatives 
are highly toxic and, thus, can be 
used for suicidal purposes. The 
neuroleptics have a much higher 
margin of safety. Anxiolytic seda-
tives raise the convulsive threshold 
and, thus, have an anticonvulsant 
effect, whereas most of the neuro-
leptics lower the convulsive thresh-
old and, in high doses, may 
induce convulsions. Most of the 
anxiolytic sedatives can produce 
tolerance and psychological de-
pendence, and many drugs in this 
category will produce physical de-
pendence when taken in high doses 
over long periods of time. The 
neuroleptics produce neither toler-
ance nor psychological dependence. 
Only anxiolytic sedatives will pro-
duce disinhibition of higher nerv-
ous processes and, thus, like 
alcohol, induce a phase of in-
creased and uncontrolled behavioral 
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manifestations prior to their inhibi-
tory action. Neuroleptics inhibit 
only; they do not induce states of 
transient disinhibition. On the other 
hand, only neuroleptic drugs can 
produce extrapyramidal side ef-
fects, e.g., parkinsonism-Iike rigid-
ity, tremor or muscular dystonia 
and dyskinesia. 
Since both types of drugs, the 
minor or the major tranquilizers, 
can be used for the management 
of acute excitement or tension and 
anxiety states, what factors should 
determine our choice of drugs in 
these conditions? The physician 
who is faced with an extremely ex-
cited patient is often inclined to 
choose what he thinks would be 
the most rapid way of subduing the 
agitated patient, i.e., by intravenous 
injection of a sedative drug. It is 
not advisable to inject neuroleptic 
drugs intravenously in a patient 
whose reactions one does not know 
very well; there may be a sudden 
marked drop of blood pressure or 
other undesirable complications. 
Therefore, the drugs chosen for 
intravenous administration should 
be those belonging to the category 
of anxiolytic sedatives. Barbiturates, 
e.g. , sodium amytal, in doses of 
250 to 500 mg; chlordiazepoxide 
(Librium), in doses of 50 to 100 
mg; or diazepam (Valium), in 
doses of 10 to 30 mg, are often 
dramatically effective in terminat-
ing a state of acute excitement. 
However, occasionally the patient 
does not calm down until very 
large doses have been administered, 
thus making the patient toxic and 
comatose. This difficulty occurs 
most frequently in states of hysteri-
cal excitement. Because of these 
occasional complications with the 
intravenous administration of anx-
iolytic sedatives, and also because 
this type of drugs in large doses 
tends to make the patient confused, 
I feel that it is generally better 
practice to rely on the intramus-
cular administration of neuroleptics 
for the management of acute ex-
citement. Most agitated patients 
will settle down after an intramus-
154 
cular injection of 50 to 100 mg 
of chlorpromazine (Thorazine) or 
thioridazine (Mellaril). Once 
calmed by these drugs, the pa-
tients also tend to become more 
rational and cooperative rather 
than confused or comatose, as with 
the anxiolytic sedatives. 
Not every agitated patient can 
be controlled with one injection of 
a neuroleptic. The physician should 
always consider a state of acute ex-
citement as an acute emergency and 
should no more abandon a patient 
before his excitement has been 
brought under control, than he 
would abandon a patient before 
shock or hemorrhage had been 
brought under control. The effects 
of an intramuscularly administered 
neuroleptic manifest themselves 
after about 15 to 20 minutes. If at 
that time the patient is still excited, 
another dose of the neuroleptic, 
either equal to the first dose or 
somewhat reduced, should be in-
jected. After another 15 minutes a 
third injection might be given and, 
sometimes, still a fourth 15 to 20 
minutes later. By that time, how-
ever, even the most excited patient 
should be under control with this 
cumulative intermittent or staggered 
sedation. 
Tension and Anxiety 
The treatment of anxiety and ten-
sion states by drugs is only a symp-
tomatic approach to the underlying 
problem-a symptomatic approach 
which should be limited to the 
shortest possible period of time. 
The treatment of choice in all anx-
iety states is psychotherapy, unless 
the tension and anxiety is due to 
physical causes, for instance, hyper-
thyroidism or congestive failure . 
It is obvious that any physical 
causes of tension and anxiety 
should receive specific treatment, 
but in the majority of cases, ten-
sion and anxiety are due to psy-
chological causes, e.g., environmen-
tal stress, personality disorders or 
intrapsychic conflicts. For these 
conditions the treatment of choice 
is psychotherapy, including the re-
cent modifications of milieu ther-
apy and behavior therapy. 
As supportive therapy for a 
limited period of time, anxiolytic 
sedatives, or the minor tranquil-
izers, are very effective in checking 
symptoms of anxiety and tension . 
The neuroleptics or major tranquil-
izers ("major," because they are 
capable of suppressing psychotic 
symptoms as well as anxiety sym-
toms) are less effective in reducing 
anxiety than the minor tranquiliz-
ers. However, the minor tranquiliz-
ers tend to produce tolerance and 
drug dependence and, thus, become 
dangerous drugs if prescribed in 
large doses for more than two or 
three weeks. Tolerance and drug 
dependence do not develop with the 
neuroleptics, and for this reason 
one may sometimes choose to pre-
scribe a neuroleptic drug for a pa-
tient suffering from anxiety, even 
though it is likely to be Jess effec-
tive than an anxiolytic sedative. 
Such a choice would be indicated 
if, on the basis of the patient's pre-
vious history or his personality 
structure, one has reason to believe 
that he might rapidly develop psy-
chological and, also, physical de-
pendence on an anxiolytic sedative. 
When faced with this hazard it is 
often wiser to choose the second 
best drug, e.g., a phenothiazine 
drug in small doses rather than a 
minor tranquilizer for sedation. 
Of all psychiatric conditions 
which a physician is called upon to 
treat, anxiety is undoubtedly the 
most common. It is difficult to re-
sist the urgent demands of an anx-
ious patient for immediate relief 
from his symptoms. The doctor 
mus.t learn to brace himself against 
these demands and persuade his pa-
tient to settle for less than complete 
relief, particularly if tranquilizing 
drugs have to be prescribed for 
periods exceeding two or three 
weeks. Patients who present anxiety 
symptoms are often highly sensitive 
to side effects which may be asso-
ciated with the use of major tran-
quilizers, and they will make every 
effort to convince the doctor that 
they ought to receive a drug which 
does not cause them any discom-
fort. However, patients should 
learn to accept the comparatively 
mild inconveniences of side effects, 
e.g., dry mouth, stuffy nose, even 
some drowsiness and lack of 
energy. It is probable that major 
tranquilizers produce less depen-
dence, precisely because they tend 
to produce more unpleasant side 
effects than the minor tranquilizers. 
When the dangers of drug toxicity, 
development of tolerance and de-
pendency are threatening, the ther-
apeutic "elegance" of prescribing 
a drug with no unpleasant side ef-
fects should definitely be disre-
garded. 
Although barbiturates are the 
principal offenders in producing 
drug dependence and toxic symp-
toms, it is a fact that almost every 
minor tranquilizer has these poten-
tials. There is no pharmacological 
reason for making a distinction be-
tween hypnotic drugs and anxioly-
tic sedatives. Every drug which is 
used primarily for sleep induction 
can also be used in smaller doses 
as a daytime sedative, and every 
daytime sedative (or minor tran-
quilizer) in larger doses will pro-
duce drowsiness and sleep. The dis-
tinction between hypnotics and 
sedatives is, thus, only a question 
of dosage. Minor tranquilizers 
other than barbiturates, e.g., methy-
prylon, or Noludar (Jensen, 1960; 
Peters, 1966), and glutethimide, or 
Doriden (Ossenfort, 1957; Ling!, 
1966), are just as likely to produce 
psychological and physical depen-
dence with dangerous withdrawal 
symptoms as are the barbiturates. 
To a lesser degree this is also true 
for meprobamate (Equanil) and 
even chlordiazepoxide (Librium) 
and diazepam (Valium), although 
physical dependence on the latter 
two drugs is rarely seen. Librium 
has the best safety record of all 
minor tranquilizers; no death has 
been reported with this drug, al-
though, with large doses, a number 
of suicidal attempts have been made. 
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The only minor tranquilizer 
which seems to be free of the po-
tential hazard of inducing physical 
drug dependence is tybamate. With 
this drug it has been impossible to 
induce physical dependence in ani-
mals or humans under experimental 
conditions, and dependence on the 
drug has not been reported under 
clinical conditions. This may be 
due to the fact that tybamate has 
an unusually short half-life in the 
organism; its rapid degradation may 
prevent the development of depend-
ence through the absence of any 
cumulative effects (Shelton and 
Hollister, 1967). Looking for a 
drug to be less likely to induce psy-
chological dependence, we have 
noted that one of the new minor 
tranquilizers, hydroxyzine (Atarax), 
is less likely than other sedatives 
to be taken in larger doses or for 
a longer time than prescribed-
possibly because it causes euphoria 
and disinhibition less frequently 
than most of the other minor tran-
quilizers. 
In summing up the salient fea-
tures regarding clinical use of anxi-
olytic sedatives, we arrive at the 
following conclusions. Anxiolytic 
sedatives, which are also called 
minor tranquilizers, differ from 
hypnotic drugs only in dosage. 
Pharmacological and psychological 
effects of all drugs in this category 
are very similar, regardless of the 
chemical nature of the drug. Many 
of the drugs in this category are 
highly toxic; therefore, no patient 
should be given a prescription for 
more than 15 doses of a barbiturate 
or meprobamate at one time. With 
very few exceptions, all anxiolytic 
sedatives tend to produce tolerance 
and psychological and physical de-
pendence. There is cross-tolerance 
between all drugs in this category, 
e.g., between alcohol and paralde-
hyde, or alcohol and Librium, or 
barbiturates and Librium. Once 
physical dependence on a minor 
tranquilizer has developed, abrupt 
withdrawal is potentially dangerous 
and should always be undertaken 
in a hospital setting. The safest 
drug from the toxicity point of view 
seems to be chlordiazepoxide; from 
the point of view of physical de-
pendence, tybamate; and from the 
point of view of psychological de-
pendence, hydroxyzine. Pharma-
cotherapy of anxiety and tension 
symptoms is always symptomatic 
and should only be used as an ad-
junct to other more specific ther-
apy. One should avoid prescribing 
the same minor tranquilizer for 
more than two weeks, unless the 
patient receives only small doses. It 
is advisable for a doctor to become 
familiar with three or four minor 
tranquilizers at the most and to al-
ternate their use if anxiety-relieving 
drugs have to be prescribed for 
more than two weeks or if special 
indications, e.g., danger of suicide 
or addiction are present. 
Acute Psychotic States 
Acute psychotic episodes fre-
quently improve within a few days 
with the use of neuroleptic (anti-
psychotic) drugs. In previous years 
these states usually lasted for 
months, and even with shock ther-
apy more time was required for 
a successful resolution of symtoms 
than is required today with pharma-
cotherapy. 
The prototype of neuroleptic 
drugs is Thorazine, which still 
serves as a standard against which 
newer drugs in the neuroleptic cate-
gory are evaluated. Thorazine is a 
phenothiazine derivative, as are 
most of the other antipsychotic 
drugs on the market today. In re-
cent years, the butyrophenones and 
thioxanthenes, derivatives of two 
other chemical structures, have 
joined the phenothiazines as power-
ful neuroleptic agents. 
The neuroleptic drugs, which are 
mainly used in the treatment of 
psychotic conditions, may be di-
vided into two groups: 1) those 
with side effects manifesting them-
selves mainly in disturbances of 
autonomic functions (hypertension, 
miosis, tachycardia, dry mouth, 
excessive perspiration and other 
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symptoms of adrenergic-cholinergic 
imbalance); and 2) those with side 
effects expressed mainly in the ex-
trapyramidal system (parkinson-
ism, akathisia, muscular dystonia 
and dyskinesia). If the drug is a 
phenothiazine derivative, the na-
ture of its side effects can usually 
be predicted from the side chain 
which is attached to the phenothia-
zine nucleus. Drugs containing a 
piperazine ring in the side chain are 
more potent, milligram for milli-
gram and produce extrapyramidal 
symptoms more frequently than 
drugs with an aliphatic side chain 
which, in turn, are more likely to 
produce changes in autonomic func-
tions and sedation and must be 
given in larger doses. Despite their 
designation as major tranquilizers, 
not all neuroleptic drugs produce 
sedation. Some of them have dis-
tinctly stimulant effects and may 
even increase tension in the pa-
tient if one of their side effects 
is akathisia, i.e., the inability of 
the patient to remain still. The 
hyperkinetic extrapyramidal symp-
tom of akathisia, as well as the 
hypokinetic symptom of rigidity, 
may be so disturbing to the patient 
that antiparkinsonism drugs must 
be employed to counteract these 
symptoms. The most frequently 
used drugs for this purpose are: 
trihexyphenidyl hydrochloride (Ar-
tane), benzotropine methanesulfo-
nate (Cogentin) and procyclidine 
hydrochloride (Kemadrin) . All of 
these antiparkinsonism drugs have 
a strong anticholinergic action. We 
have found that they may produce 
toxic psychotic symptoms if they 
are given in daily doses exceeding 
six or eight mg of Artane or Cogen-
tin, or 15 mg of Kemadrin. 
Most neuroleptic drugs have re-
markably low toxicity and an extra-
ordinarily wide therapeutic margin, 
but they also have an unusually 
broad range of unpleasant side ef-
fects, such as somnolence, apathy 
and restlessness, extrapyramidal 
symptoms, dryness of the mucous 
membranes, tachycardia, hypoten-
sion, disturbances of accommoda-
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tion, constipation, obesity, menstrual 
irregularity and photosensitization. 
Skin rashes, edema, leucopenia and 
cholestatic jaundice may occur as 
symptoms of idiosyncratic hyper-
sensitivity. Rarely, agranulocytosis 
and venous thrombosis are seen. 
With very large doses of neurolep-
tics-over I 000 mg of Thorazine 
a day or its dose equivalent-con-
vulsions may occur. 
Mellaril, the neuroleptic with the 
lowest incidence of extrapyramidal 
side effects, should not be pre-
scribed in doses exceeding a daily 
maximum of 400 to 500 mg for 
more than two or three weeks, 
since under those conditions it 
might produce irreversible retinal 
changes or dangerous cardiac ar-
rhythmias. Doses of the drug up to 
400 mg/ day seem to be well toler-
ated for an indefinite time. 
The following is a list of the most 
frequently used neuroleptics: 
1) Phenothiazine derivatives with 
an aliphatic structure in the side 
chain: chlorpromazine (Thora-
zine) ; triflupromazine (Vesprin); 
promazine ( Sparine) . 
2) Phenothiazine derivatives with 
a piperazine ring in the side chain: 
perphenazine (Trilafon) ; trifluo-
perazine (Stelazine); prochlorpera-
zine (Compazine); thiopropazate 
(Dartal) ; fluphenazine (Prolixin; 
Moditen). 
3) Phenothiazine derivatives with 
a piperidyl ring in the side chain: 
thioridazine (Mellaril). 
4) Butyrophenone derivative: hal-
operidol (Haldol). 
5) Thioxanthene derivatives: 
chlorprothixene (Taractan); thio-
thixene (Navane). 
This list is not complete, but re-
fers only to the more frequently 
used drugs in the United States. 
Specific doses for each drug can 
best be obtained from the informa-
tion provided by the manufacturer, 
although dosage information given 
on the package inserts by the manu-
facturer invariably tends to be on 
the conservative side and fre-
quently has to be exceeded in in-
dividual cases. Fortunately, this can 
be done in most cases without par-
ticular risk because of the wide 
safety margin of all neuroleptic 
drugs. 
Which of the many neuroleptics 
should one choose? Years of care-
ful clinical investigation have made 
it very clear that for all practical-
i.e., clinical-purposes, no specific 
indications or specific therapeutic 
properties exist for any of the 
neuroleptic drugs. Therefore, it is 
probably best for a physician to be-
come thoroughly familiar with two 
or three neuroleptic drugs and then 
restrict himself to their use. What 
is essential is that adequate doses 
are given over an adequate period 
of time. Such specific differences 
between the actions of various 
neuroleptic drugs as were found to 
exist were only of statistical sig-
nificance and so slight that they 
probably have no importance for 
the clinician (Goldberg et al. , 
1967) . 
What is an adequate dose? The 
table on the opposite page shows 
approximate therapeutic equiva-
lences of doses of various neuro-
leptic drugs in comparison to 
Thorazine. If I mg of Thorazine is 
taken as 1 phenothiazine unit, the 
clinical approximations shown in 
the Table are obtained. For exam-
ple, the table indicates that 10 mg 
of Trilafon are equivalent to 100 
mg of Thorazine, and I mg of Hal-
dol is equivalent to 70 mg of Thora-
zine. 
The therapeutic daily dose for 
the treatment of an acute psychotic 
reaction is between 400 and 1000 
phenothiazine units (mg of Thora-
zine or the dosage equivalent of 
other neuroleptic drugs). Some-
times higher daily dose levels are 
required, e.g., 1000 to 2000 pheno-
thiazine units and, occasionally, up 
to 3000 or 4000 units a day. But 
400 to I 000 phenothiazine units a 
day will be effective in the treat-
ment of most acute psychotic 
breakdowns. If the dose is ade-
quate, the symptoms of restlessness 
and insomnia should have subsided 
after one week of pharmacother-
apy; after two weeks of treatment 
the patient's anxiety, irritability, de-
pression, suspiciousness and social 
withdrawal should be significantly 
reduced. Only after 8 to 12 weeks 
may one expect the disappearance 
of hallucinations, delusions and 
thought disorder. In some patients 
resolution of all symptoms may, 
under adequate pharmacotherapy, 
be telescoped into a few days, par-
ticularly if the breakdown has been 
very sudden in onset. On the other 
hand, if the above timetable indi-
cates that the patient's symptoms 
are not subsiding within the ex-
pected periods of time, it may be 
necessary to increase the dose of 
the neuroleptic (Lehmann, 1965a). 
An acute psychotic condition is 
treated preferably with intramuscu-
lar injections, at least for the first 
few days; then a change to oral ad-
ministration may be instituted. The 
risk of giving too much of a neuro-
leptic drug is small if the general 
framework of the recommended 
dosage is followed and one or two 
test doses are given to observe the 
patient's initial reaction to the drug. 
Maintenance Therapy of 
Schizophrenics in Remission 
Chronic psychotic patients and 
schizophrenic patients in remission 
frequently require maintenance 
therapy with neuroleptic drugs for 
many months-sometimes for years. 
The maintenance dose in most cases 
is from one-sixth to one-fourth of 
the acute treatment dose. If main-
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tenance therapy is interrupted, the 
risk of a relapse is between 30% 
and 50% . This risk can be reduced 
to 5% or 10%, provided the patient 
remains on regular follow-up ther-
apy. At times of increased stress, 
family conflicts, job changes and 
similar problems, the maintenance 
dose may have to be increased for a 
short time; the same applies if the 
patient shows signs of increasing 
tension or instability. The clinical 
situation is similar to that of an 
epileptic patient on anticonvulsant 
treatment or of a diabetic on in-
sulin, i.e., the treatment is neither 
merely symptomatic nor curative, 
but corrective or compensating in 
nature. 
A long-acting, injectable pheno-
thiazine drug is now available in 
the form of Fluphenazine Enan-
thate. The usual dose is 1 cc, con-
taining 25 mg of the drug. For in-
dividual patients it is, of course, 
sometimes necessary to increase or 
decrease the dose, but the great ad-
vantage of this preparation is that 
the effects of one injection in most 
cases last for two weeks or longer, 
thus freeing the patient from the 
responsibility to take medication 
himself every day. All he needs to 
do is return every two or three 
weeks for his injection. Since Flu-
phenazine has a piperazine struc-
ture in its side chain, the compound 
is likely to induce extrapyramidal 
symptoms, and antiparkinsonism 
drugs might be required to counter-
act these side effects. 
Dose Equivalence of Various Neuroleptic Drugs 
Neuroleptic Drugs 
Triflupromazine (Vesprin) 
Promazine (Sparine) 
Perphenazine (Trilafon) 
Trifluoperazine (Stelazine) 
Prochlorperazine ( Compazine) 
Fluphenazine (Prolixin; Moditen) 
Thioridazine (Mellaril) 
Haloperidol (Haldol) 
Chlorprothixene (Taractan) 
Thiothixene (Navane) 
Phenothiazine Units 
3 
t 
10 
20 
6 
70 
1 
70 
1 
20 
It is true that probably 50% or 
60% of former schizophrenic pa-
tients are today receiving neurolep-
tic drug therapy for months or 
years without needing it. The trou-
ble is that we cannot tell, by any 
criterion, which of the patients are 
the 40% or 50% who will relapse 
if they do not receive maintenance 
therapy. If we have seen once that 
a patient who did not take any 
maintenance medication had a re-
lapse, we can assume with a high 
degree of probability that this pa-
tient will again relapse unless he 
receives maintenance therapy. Usu-
ally, we do not have this infor-
mation, because the patient is put 
on maintenance therapy after the 
first psychotic breakdown. In these 
cases one should continue with 
maintenance therapy for at least 
six months and then carefully try 
to withdraw the maintenance medi-
cation. Once it is known that an 
individual patient requires main-
tenance therapy, this treatment 
should have considerable priority 
over all other considerations. The 
question one would have to ask of 
oneself is whether it is more ad-
vantageous for the patient to stop 
taking his medication and be hos-
pitalized in a psychotic state or to 
continue taking his medication and 
remain a normally functioning 
member of the community suffer-
ing the inconvenience of certain 
unpleasant side effects. 
Serious complications, i.e. , agran-
ulocytosis or jaundice, very rarely 
occur after the first two months of 
pharmacotherapy. Unfortunately, 
regular blood counts and biochemi-
cal tests have hardly more than 
legal value, unless they are re-
peated every two days. Skin pig-
mentation and lens opacities (us-
ually without effect on visual 
acuity) have been described after 
more than six months' medication 
with high doses of Thorazine, and 
recently attention has been drawn 
to extrapyramidal symptoms, us-
ually involving muscles of the 
tongue and the mouth, which occur 
after long-term therapy with pipera-
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zine derivatives of the phenothia-
zines. (Unlike the extrapyramidal 
symptoms occurring under acute 
treatment conditions, these late in-
voluntary movements are usually 
irreversible. Fortunately, they oc-
cur only in a comparatively small 
percentage of patients, mostly in 
the older age group, and only after 
more than a year of continued drug 
therapy.) 
Therapeutics of Antidepressants 
The physician who has diagnosed 
his patient as being depressed and 
is considering the choice of treat-
ment must first determine how 
threatening the patient's condition 
is. Is the patient acutely suicidal? 
Does he refuse to take food or 
medication? Is he psychotic and un-
cooperative? These features may 
determine whether the patient can 
be treated at home or must be hos-
pitalized; they may also indicate 
whether the patient should receive 
immediate electro-convulsive ther-
apy or can be treated with an 
antidepressant drug. In acutely sui-
cidal patients electro-convulsive 
treatment is often indicated, since 
most antidepressant drugs take 
from one to three weeks to produce 
notable improvement. 
A differential diagnosis between 
endogenous and reactive depression 
is often helpful, because endoge-
nous depressions mainly require 
physical treatment, either electro-
convulsive treatment or pharmaco-
therapy, whereas reactive depres-
sions, which may also respond to 
physical treatments, usually require 
psychotherapy in addition to other 
treatments. Today, the extent to 
which one can really distinguish 
between purely endogenous and 
purely reactive depressions is be-
coming more and more ques-
tionable. The concept of "endo-
reactive" depression, which is used 
in the German psychiatric literature, 
reflects the state of affairs which is 
frequently encountered in depres-
sive states, i.e., one with endoge-
nous as well as reactive components. 
158 
However, it is still useful to at-
tempt an assessment of the varying 
degrees to which each of these 
two components is present in a 
given depression (Lehmann, 1965b, 
1968). 
Once the decision to use antide-
pressant drug therapy has been 
made, the choice lies between drugs 
belonging to the class of monoa-
mine oxidase inhibitors and drugs 
which are often referred to as tricy-
clic antidepressants, because their 
chemical structure is characterized 
by a three-ring nucleus. Examples of 
the first type are: phenelzine (Nar-
dil); isocarboxazide (Marplan); 
nialamide (Niamid); tranylcypro-
mine (Parnate) . Examples of the 
second group are: 1m1pramine 
(Tofranil); amitriptyline (Elavil); 
desipramine (Pertofrane, Norpra-
min); nortriptyline (Aventyl); 
protriptyline (Vivactil, Triptil). 
The monoamine oxidase inhibitors 
have approximately the same ther-
apeutic effectiveness as the tricyclic 
antidepressants, although there is 
gradually increasing evidence that 
the tricyclic antidepressants are 
slightly more effective than the 
MAO inhibitors. On the average, 
about 60% to 65% of depressed 
patients show a satisfactory im-
provement within two to three 
weeks when treated with antide-
pressant drugs. 
The physician who prescribes a 
MAO inhibitor must remember 
that the effect of this enzyme in-
hibitor is reaching farther than or-
dinary drug action, because the in-
hibition of monoamine oxidase is 
not easily reversed. Monoamine 
oxidase is the enzyme that degrades 
serotonin and noradrenaline, and 
when this enzyme is inhibited, the 
biogenic amines are allowed to accu-
mulate. A similar effect is produced 
by the tricyclic antidepressants, 
but through a different mecha-
nism; they prevent excessive nora-
drenaline, which has been freed at 
the neuronal synapses, from being 
reabsorbed into the cell body. Both 
classes of antidepressant drugs, thus, 
lead to an increase of available 
serotonin and noradrenaline at 
neuronal synapses. This has been 
advanced as an explanation of 
their antidepressant action, since 
current neurochemical theories of 
depression propose that the under-
lying physical substrate of a de-
pressive state is a reduction of the 
biogenic amines at the synapses of 
the central nervous system. 
Some MAO inhibitors, e.g., 
tranylcypromine (Parnate), have an 
immediate amphetamine-like stimu-
lating and euphorizing effect in 
addition to their principal antide-
pressant action, which can be ob-
served only after one to three 
weeks. Such stimulation is often de-
sirable, but in some cases it might 
be contraindicated. The side effects 
of MAO inhibitors are more diffi-
cult to manage than those of the 
tricyclic antidepressants, because 
MAO inhibitors are incompatible 
with many other drugs and with 
certain food substances, e.g., cheese, 
which may contain the pressor sub-
stance tyramine. It is essential that 
patients receiving a MAO inhibi-
tor abstain from these food items 
and from most other drugs, particu-
larly adrenaline, amphetamines, 
thyroid and Demerol which, in 
combination with a MAO inhibi-
tor, may precipitate very alarming 
toxic complications. MAO inhibi-
tors and tricyclic antidepressants 
should not be administered simul-
taneously, and at least a week 
should elapse after discontinuation 
of a MAO inhibitor before treat-
ment with a tricyclic antidepres-
sant is instituted. 
Tricyclic antidepressants produce 
mainly anticholinergic side effects; 
hence, care should be exercised 
when ordering these drugs for pa-
tients in whom urinary retention 
or glaucoma may be precipitated. 
A tricyclic antidepressant should 
never be administered concurrently 
with both an antiparkinsonism drug 
and a neuroleptic, since all three 
drugs-particularly the first two-
have anticholinergic properties and 
may act synergistically to produce 
dangerous and even fatal complica-
tions, e.g., adynamic ileus (Warnes, 
Lehmann and Ban, 1967). Some 
caution is also indicated in patients 
with myocardial damage in whom 
tricyclic antidepressants may pro-
duce reversible cardiac arrhythmias. 
Some antidepressant drugs, e.g., 
amitriptyline (Elavil), also have 
anxiety-reducing effects. Patients 
suffering from an anxious or agi-
tated type of depression often re-
spond favorably to minor or major 
tranquilizers, e.g., Equanil, Librium 
or Mellaril. Anxiety is very fre-
quently associated with depression, 
and since the manifestations of 
anxiety are far more conspicuous 
than the manifestations of depres-
sion, there is a danger that the les-
sening of anxiety in response to a 
drug is mistaken for an overall im-
provement in the depressed pa-
tient's condition. If this happens, 
one may relax one's vigilance when 
treating a patient who, in initial 
response to therapy, may sleep bet-
ter, look better and display less 
anxiety, but may still feel depressed 
and hopeless and may also still be 
suicidal. The core symptom of de-
pression is a feeling of sadness, 
despair, pessimism and hopeless-
ness and the inability to get in-
volved with things or people. Until 
these core symptoms have subsided, 
a depressed patient's improvement 
is far from complete. 
After the depressed patient's 
symptoms have disappeared, drug 
therapy should be continued for at 
least two to three months at the 
same dosage; after this time the 
dose of the antidepressant might 
be reduced to about one-half or 
one-third for another month or 
two. 
For patients with frequently re-
current depressions or patients who 
have many recurring manic or de-
pressive episodes, lithium has re-
cently been shown to offer valuable 
prophylactic action. The therapeu-
tic effects of lithium carbonate in 
states of manic excitement have 
been known for 20 years. However, 
the drug seems to have few, if 
any, therapeutic effects in depres-
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sive states. Recently, Baastrup and 
Schou ( 1967) have shown that 
lithium carbonate, in doses of about 
one-third or one-half of the thera-
peutic dose in manic conditions, 
can be given as successful main-
tenance treatment to prevent the . 
recurrence of both manic or de-
pressive episodes. This is a con-
siderable step forward , because 
maintenance treatment for affective 
disorders previous to the introduc-
tion of lithium treatment has by no 
means been as effective as main-
tenance treatment of schizophrenic 
patients in remission. However, be-
fore treatment with lithium carbon-
ate is instituted, a careful history 
should be taken and the differ-
ential diagnosis should be well 
established, since this form of ther-
apy does not seem to be effective 
in schizophrenic conditions and 
would not be indicated for manic 
or depressive episodes which occur 
only at long intervals. Since lithium 
may cause dangerous toxic compli-
cations which may be fatal , it is 
essential for patients on lithium 
therapy to have their lithium blood 
level monitored at regular intervals. 
Alcoholism and Antabuse 
Drugs are of no value in the 
treatment of most personality dis-
orders, for instance, antisocial be-
havior and sexual deviation. Some 
drugs can play an important role 
in the rehabilitation of opiate ad-
dicts, e.g. , methadone, which, in the 
first few years of a large-scale trial 
in New York City, has shown re-
markable results (Dole, Nyswander 
and Warner, 1968; Methadone 
Maintenance Evaluation Commit-
tee, 1968). However, the treatment 
of addicts has not yet progressed to 
the point where the non-specialist 
may be advised to undertake it. 
But there is one kind of addiction, 
i.e., alcoholism, which is so wide-
spread-there are over two million 
alcoholics in the United States-
that non-specialist physicians must 
accept a major part of the respon-
sibility for treating this group of 
patients. Treatment of the alco-
holic is a complex problem and 
involves the application of almost 
every medical skill, but in the 
framework of this discussion, I want 
to draw your attention to one phar-
macotherapeutic approach which is 
specifically applicable to the treat-
ment of alcoholism. I am referring 
to the use of disulfiram (Antabuse) 
as a maintenance treatment for al-
coholics who are motivated to give 
up drinking. 
Antabuse is an enzyme inhibitor 
which blocks the breakdown of al-
cohol in the organism at the acetal-
dehyde stage. Since acetaldehyde is 
a highly toxic substance, people 
who have taken Antabuse and later 
take alcohol become very ill within 
a matter of minutes. The alcoholic 
who takes his Antabuse medication 
regularly will usually be deterred 
from taking alcohol by his knowl-
edge of the ordeal he would have 
to endure. The drug thus serves as 
a chemical straitjacket, a most val-
uable aid to those who are seri-
ously motivated to give up drink-
ing, but is not of much value to 
those who simply stop taking Anta-
buse when they feel the desire to 
drink. 
Summary 
Psychopharmacology has opened 
the door to many previously blocked 
parts of psychiatric therapy. It has 
been a welcome catalyst for a long 
awaited rapprochement between 
psychiatry and the rest of medicine. 
Even if psychopharmacological re-
search is not likely to produce an-
other revolutionary "breakthrough" 
type of drug in the near future, 
there is good reason to expect many 
more useful therapeutic tools to is-
sue from such research in the years 
to come. 
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